Kytril

Granisetron, the active ingredient in Kytril, is a selective 5‑HT3 receptor antagonist presented as an oral tablet. It is used to prevent and treat nausea and vomiting that can occur in patients receiving chemotherapy or undergoing surgical procedures, providing an important antiemetic option in oncology and peri‑operative care.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier, serving hospitals, oncology centres, pharmacies and clinics worldwide with consistent quality and regulatory compliance. Our distribution network ensures timely delivery and support for procurement teams across multiple regions.

Kytril (granisetron) is a 5‑HT3 receptor antagonist used to control nausea and vomiting related to specific therapeutic pathways.

Chemotherapy-induced nausea and vomiting: prevents and reduces acute and delayed nausea and vomiting in patients receiving cytotoxic chemotherapy. Postoperative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures. Radiation therapy-induced nausea and vomiting: helps control nausea associated with radiotherapy treatments.

Adverse reactions to Kytril may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Constipation: reduced bowel movements that may require dietary adjustment. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty. - QT‑interval prolongation: cardiac rhythm disturbance that can lead to arrhythmia. - Severe constipation or bowel obstruction: persistent blockage requiring medical intervention. - Cardiac arrhythmias: irregular heartbeats that may be life‑threatening.

Before prescribing Kytril, clinicians should consider several safety factors.

Assess cardiac risk: evaluate patient history for QT prolongation or arrhythmias. Monitor electrolytes: correct imbalances that could exacerbate cardiac effects. Evaluate hepatic function: adjust use in patients with significant liver impairment. Use caution with concomitant QT‑prolonging drugs: avoid combining with other agents that affect cardiac repolarization. Avoid in known hypersensitivity: do not administer to patients allergic to granisetron or excipients. Store at room temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Granisetron may interact with other medications, requiring attention to potential effects.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use can increase toxicity. - QT‑prolonging agents (e.g., quinidine, haloperidol): may heighten risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise granisetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Other antiemetics (e.g., metoclopramide): monitor for additive side effects. - Opioids: increased risk of constipation when combined.